NCT00961766View on ClinicalTrials.gov

Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Sciatica
Interventions
DRUG

BG00010 (Neublastin)

Single dose, weight-based IV administration

DRUG

Placebo

Single dose IV matched placebo

Trial Locations (1)

5000

Research Site, Adelaide

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY